Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head...
Buybacks are getting a boost at three $20B to $200B firms. Does Trade Desk's repurchase authorization signal confidence, or is it too early to tell?
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing...
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Vaxcyte, with a price target of $85.00. The company’s shares closed yesterday at $43.94.Elevate Your Investing Strategy:...
In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte, with a price target of $134.00. The company’s shares closed yesterday at $40.13.Elevate...
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS,...
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal...
A volatile market presents the perfect opportunity to grab outstanding stocks at a bargain.